Clinical Trial Update: A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients. [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing Prograf and Prograf-XL in de novo liver transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant Rejection

Drugs mentioned

• Prograf (Tacrolimus)
• Prograf-XL (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Liver Transplantation, Transplantation Immunology | Phase 3 | Status: COMPLETED